Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2022-03-30 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
启迪药2022年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a 2022 restricted stock incentive plan by 启迪药业集团股份公司. It details the purpose, principles, scope, assessment criteria, procedures, and management of the stock incentive plan. It is a policy or procedural document related to stock incentives and employee performance assessment rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or results but rather governance and management rules for the incentive plan. Therefore, it fits best under Governance Information (CGR), which covers internal rules and governance practices related to the company.
2022-03-30 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is a detailed report from the board of directors regarding the storage and usage of funds raised in 2021. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, discusses the amounts raised, usage by year, management of funds, investment projects, and includes an auditor's verification opinion. The document is titled as a "special report" on the use of raised funds for the year 2021. It is not a general annual report, earnings release, or management discussion, but a focused report on fundraising and capital usage. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length and detail confirm it is a full report, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2022-03-30 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of various reports and proposals related to the 2021 fiscal year, including the 2021 Supervisory Board Work Report, 2021 Annual Report, 2021 Financial Statements, Profit Distribution Plan, Internal Control Evaluation Report, and other related matters. It includes voting results and mentions that some proposals will be submitted to the shareholders' meeting for approval. The document length is 3706 characters, which is relatively short and mainly consists of meeting resolutions and approvals rather than the full reports themselves. The document also references that the full 2021 Supervisory Board Work Report is published elsewhere (on a website). This indicates that the document is an announcement of meeting resolutions and approvals rather than the full annual report or financial statements. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not contain the full report content themselves.
2022-03-30 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to use part of its idle raised funds temporarily to supplement working capital. It details the board and supervisory committee meetings approving this use, the amount involved, and assurances that this will not affect the original investment projects. The document includes opinions from independent directors and the sponsoring institution's verification. The content focuses on the use of raised funds and related approvals rather than presenting financial statements or comprehensive financial data. The document length is about 3400 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this is a Capital/Financing Update (CAP) filing, as it relates to the use and management of raised capital funds.
2022-03-30 Chinese
中德证券有限责任公司关于启迪药业集团股份公司使用部分募集资金用于暂时补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Zhongde Securities regarding the use of part of the raised funds by Qidi Pharmaceutical Group Co., Ltd. for temporarily supplementing working capital. It references regulatory approvals, fundraising details, fund usage plans, and approvals by the board, supervisory committee, and independent directors. The document is focused on the use and management of raised funds, specifically related to a non-public stock issuance and the temporary use of idle raised funds. It is not a full financial report, earnings release, or audit report, but rather a regulatory compliance and verification opinion related to capital use. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is 3357 characters, which is substantive and not a mere announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2022-03-30 Chinese
中德证券有限责任公司关于启迪药业集团股份公司2021年度募集资金存放与使用的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from Zhongde Securities regarding the 2021 annual special inspection of the storage and use of raised funds by Qidi Pharmaceutical Group Co., Ltd. It includes extensive financial data on the amount of funds raised, their usage over multiple years including 2021, balances in special accounts, investment projects, changes in project implementation, and compliance with regulatory requirements. It also contains an auditor's verification opinion and the sponsor's verification opinion. The document references regulatory guidelines and laws related to the management and use of raised funds. The length is over 10,000 characters and contains substantive financial and operational data about the use of raised funds for the fiscal year 2021. This matches the characteristics of an Audit Report / Information (AR) as it is a standalone audit and verification report on the use of raised funds, not a full annual report or earnings release. It is not a simple announcement or certification but a comprehensive audit-related report on a specific topic (fundraising usage). FY 2021
2022-03-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.